US generic pricing pressure
US generics declined due to additional competition and pricing pressure, which may continue.
SUNPHARMA / Q4-FY25 / risks
Keep the risk register visible.
Sunpharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
MFN/tariff policy uncertainty
Lack of clarity on MFN and tariff policies could impact US specialty pricing and access.
Leqselvi patent litigation risk
Leqselvi launch may be at risk due to ongoing patent litigation; potential damages if lost.
Tax rate increase
Effective tax rate rose to 19.8% in Q4 from 5.1% last year, expected to inch up further.